{
    "nctId": "NCT00909506",
    "briefTitle": "Efficacy and Safety of Adjuvant Metformin for Operable Breast Cancer Patients",
    "officialTitle": "N/A",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 105,
    "primaryOutcomeMeasure": "Weight loss",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Operable Breast cancer patients with BMI \u2265 23 or 100 \u2264 FBS \\< 126\n* From 6 month to 2 years since breast cancer operation and at least 4 weeks since chemotherapy or radiotherapy\n* No drug use except Tamoxifen\n* Normal OTPT \\& Serum creatinine (\\<=ULN)\n* ECOG performance status 0-2 or Karnofsky PS 60-100%\n* Life expectancy \\> 12\n* Absolute neutrophil count \u2265 1.5 x 10\\^9/L\n* Platelets \u2265 100 x 10\\^9/L\n* Pregnancy(-) \\& without plan for pregnancy\n* Sign a written informed consent form\n\nExclusion Criteria:\n\n* Type I or II DM or concurrent use of DM control agents\n* Prior use of Metformin\n* Hypoglycemia (FBS\\< 70 with clinical symptom)\n* Concurrent investigational or commercial agents\n* Other diet or drug intervention for weight loss\n* Concurrent use of steroid\n* Abnormal liver and/or renal function\n* Symptomatic congestive heart failure / Cardiac arrhythmia / Angina pectoris\n* Ongoing or active infection\n* lactic acidosis\n* Pregnancy or ongoing breast feeding\n* Anorexia, bulimia, nausea due to other disease for longer than 1 month\n* Allergies or allergic reactions attributed to oral medications\n* Inability to swallow or digest oral medications\n* Physical or psychiatric illness that would limit compliance with study protocol\n* Participants in other clinical trial",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}